Literature DB >> 10471577

In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.

A Kutlin1, P M Roblin, M R Hammerschlag.   

Abstract

Chlamydia pneumoniae is a well-established cause of community-acquired pneumonia and bronchitis in adults and children. Chronic infections with C. pneumoniae have been implicated in the development of atherosclerosis and other diseases in humans. Methods currently used for the culture and propagation of C. pneumoniae are not analogous to the infection as it occurs in vivo. We have established a model of continuous C. pneumoniae infection in vitro. HEp-2 cells inoculated with CM-1 and TW-183 strains have been persistently infected for periods of over 1.5 and 2 years, respectively. The cultures were maintained without centrifugation or the addition of cycloheximide, fresh host cells, or chlamydia. We observed cycles of host cell lysis, detachment, and regrowth with both strains of C. pneumoniae. Continuous C. pneumoniae infections may more closely resemble the actual events as they occur in vivo and, therefore, may be a better model for the in vitro study of C. pneumoniae infection. When we used continuously infected cells to determine the effects of azithromycin and ofloxacin on C. pneumoniae propagation in vitro, we found that both drugs reduced but did not completely eliminate the organism. This may be an important observation, as the failure of antibiotic therapy against C. pneumoniae infection in humans has been described.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471577      PMCID: PMC89459     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Persistent infection of HeLa cells with meningopneumonitis virus.

Authors:  G P MANIRE; G J GALASSO
Journal:  J Immunol       Date:  1959-11       Impact factor: 5.422

2.  Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.

Authors:  P M Roblin; W Dumornay; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

3.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors:  M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

4.  Persistent infection of mouse fibroblasts (McCoy cells) with a trachoma strain of Chlamydia trachomatis.

Authors:  C K Lee; J W Moulder
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

5.  Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries.

Authors:  C C Kuo; A Shor; L A Campbell; H Fukushi; D L Patton; J T Grayston
Journal:  J Infect Dis       Date:  1993-04       Impact factor: 5.226

6.  In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; C L Hyman; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

7.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.

Authors:  P Saikku; M Leinonen; L Tenkanen; E Linnanmäki; M R Ekman; V Manninen; M Mänttäri; M H Frick; J K Huttunen
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

9.  Spread and persistence of infection with a trachoma biovar strain of Chlamydia trachomatis in multiplying and nonmultiplying McCoy cells.

Authors:  S Benes
Journal:  Sex Transm Dis       Date:  1990 Jan-Mar       Impact factor: 2.830

10.  Persistent infection of mouse fibroblasts (L cells) with Chlamydia psittaci: evidence for a cryptic chlamydial form.

Authors:  J W Moulder; N J Levy; L P Schulman
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

View more
  23 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model.

Authors:  A Kutlin; C Flegg; D Stenzel; T Reznik; P M Roblin; S Mathews; P Timms; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 3.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

4.  Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Authors:  Paul F Riska; Andrei Kutlin; Patrick Ajiboye; Arnold Cua; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 5.  Chlamydial persistence: beyond the biphasic paradigm.

Authors:  Richard J Hogan; Sarah A Mathews; Sanghamitra Mukhopadhyay; James T Summersgill; Peter Timms
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

6.  First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae.

Authors:  Jens Gieffers; Jan Rupp; Andreas Gebert; Werner Solbach; Matthias Klinger
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 7.  Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember?

Authors:  Kensuke Shima; Gregor Kuhlenbäumer; Jan Rupp
Journal:  Med Microbiol Immunol       Date:  2010-05-06       Impact factor: 3.402

Review 8.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

9.  Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts.

Authors:  Laura Mannonen; Eveliina Markkula; Mirja Puolakkainen
Journal:  Med Microbiol Immunol       Date:  2011-01-30       Impact factor: 3.402

10.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.